title: The neuroprotective effect of lovastatin on MPP(+)-induced neurotoxicity is not mediated by PON2.
abstract: Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of the pigmented dopaminergic neurons in the substantia nigra pars compacta with subsequent striatal dopamine (DA) deficiency and increased lipid peroxidation. The etiology of the disease is still unclear and it is thought that PD may be caused by a combination of genetic and environmental factors. In the search of new pharmacological options, statins have been recognized for their potential application to treat PD, due to their antioxidant effect. The aim of this work is to contribute in the characterization of the neuroprotective effect of lovastatin in a model of PD induced by 1-methyl-4-phenylpyridinium (MPP(+)). Male Wistar rats (200-250 g) were randomly allocated into 4 groups and administered for 7 days with different pharmacological treatments. Lovastatin administration (5 mg/kg) diminished 40% of the apomorphine-induced circling behavior, prevented the striatal DA depletion and lipid peroxides formation by MPP(+) intrastriatal injection, as compared to the group of animals treated only with MPP(+). Lovastatin produced no change in paraoxonase-2 (PON2) activity. It is evident that lovastatin conferred neuroprotection against MPP(+)-induced protection but this effect was not associated with the induction of PON2 in the rat striatum.
authors.affiliation: Laboratorio de Neuroprotección, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.
authors.forename: Yoshajandith
authors.initials: Y
authors.lastname: Aguirre-Vidal
authors.affiliation: Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía, M.V.S., D.F., Mexico.
authors.forename: Sergio
authors.initials: S
authors.lastname: Montes
authors.affiliation: Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía, M.V.S., D.F., Mexico.
authors.forename: Luis
authors.initials: L
authors.lastname: Tristan-López
authors.affiliation: Laboratorio de Neuroprotección, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.
authors.forename: Laura
authors.initials: L
authors.lastname: Anaya-Ramos
authors.affiliation: Division of Epidemiology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: John
authors.initials: J
authors.lastname: Teiber
authors.affiliation: Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía, M.V.S., D.F., Mexico; Laboratorio de Neurofarmacologia Molecular, Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, D.F., Mexico.
authors.forename: Camilo
authors.initials: C
authors.lastname: Ríos
authors.affiliation: Laboratorio de Neurofarmacologia Molecular, Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, D.F., Mexico.
authors.forename: Verónica
authors.initials: V
authors.lastname: Baron-Flores
authors.affiliation: Laboratorio de Neuroprotección, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico. Electronic address: amonroy@uaem.mx.
authors.forename: Antonio
authors.initials: A
authors.lastname: Monroy-Noyola
mesh_terms: D015655:1-Methyl-4-phenylpyridinium; D000818:Animals; D043303:Aryldialkylphosphatase / Q000378:metabolism*; D001522:Behavior, Animal / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects* / Q000201:enzymology / Q000503:physiopathology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008054:Lipid Peroxides / Q000378:metabolism; D008148:Lovastatin / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology*; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000201:enzymology / Q000503:physiopathology / Q000517:prevention & control*; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D008054:Lipid Peroxides; D018696:Neuroprotective Agents; D008148:Lovastatin; D043303:Aryldialkylphosphatase; C000605116:paraoxonase 2, rat; D015655:1-Methyl-4-phenylpyridinium; D004298:Dopamine
keywords: Dopamine; Lipoperoxidation; Lovastatin; Paraoxonase-2; Parkinson